||This article needs additional citations for verification. (March 2009)|
Sudafed is a brand name and registered trademark for over the counter (OTC) decongestants manufactured by McNeil Laboratories (a division of Johnson & Johnson) for sale in Australia, New Zealand, Canada, Ireland, South Africa, the United Kingdom, and the United States. Before being acquired by Johnson & Johnson in 2006, Sudafed was owned by Pfizer.
Summary of active ingredients 
The brand name Sudafed is used for several formulations that contain different active ingredients:
- The active ingredient (as the hydrochloride salt) of the original Sudafed. In the UK, this is now sold under the name "Sudafed Decongestant".
- Phenylephrine (hydrochloride)
- These products are sold as alternatives to pseudoephedrine formulations. In the United Kingdom, formulations containing phenylephrine are sold under various names (Sudafed Blocked Nose capsules, Sudafed Blocked Nose & Sinus capsules, Sudafed Mucus Relief Triple Action Cold & Flu tablets, Sudafed Sinus Pressure & Pain tablets, and Sudafed Day & Night capsules). In other countries the name "Sudafed PE" is used.
- Oxymetazoline (hydrochloride)
- The active ingredient in products using the name Sudafed OM in the United States; these are formulated as topical nasal sprays.
- Xylometazoline (hydrochloride)
- The active ingredient in a product formulated as topical nasal spray and sold in the United Kingdom under the name Sudafed Blocked Nose Spray.
In the UK, some Sudafed-branded products containing phenylephrine also contain other active ingredients:
- Sudafed Blocked Nose capsules, Sudafed Blocked Nose & Sinus capsules, Sudafed Day & Night capsules, and Sudafed Mucus Relief Triple Action Cold & Flu tablets
- Sudafed Sinus Pressure & Pain tablets
- Sudafed Day & Night capsules (day capsules only) and Sudafed Blocked Nose & Sinus capsules
- Sudafed Mucus Relief Triple Action Cold & Flu tablets
Switch to phenylephrine 
||The examples and perspective in this article may not represent a worldwide view of the subject. (October 2012)|
In late 2004, Pfizer publicly disclosed its plans to make available a new over-the-counter product, Sudafed PE, which does not include pseudoephedrine. Decongestants with other ingredients were completely converted to phenylephrine later in 2005. Original Sudafed is still offered behind the counter to customers 18 years of age or older upon request, requiring the customer to show ID and sign a sales log next to a record of their name and address.
The new product was prompted by existing and proposed restrictions on the availability of pseudoephedrine-based products. U.S. state laws imposing such restrictions were in response to pseudoephedrine's role as an ingredient used to synthesize the stimulant methamphetamine.
Pfizer and its predecessor Warner-Lambert had studied at least two alternatives to the pseudoephedrine-containing formula in anticipation of pressure from state regulators and the Food and Drug Administration:
- In 1996, the company began testing a patented decongestant ingredient known as "minus" pseudoephedrine. The company claimed animal tests showed this altered version offered sinus relief comparable to the current "plus" pseudoephedrine. The difference was that it couldn't be converted to methamphetamine, a prescription only drug used recreationally. Pfizer did not bring the new ingredient to market because of the cost and time involved in gaining regulatory approval.
- Pfizer spent US$12 million trying to develop additives for Sudafed that might make it harder to remove the pseudoephedrine it contains. They abandoned the project in 2003, seven years after announcing its existence.
Several pharmacists have questioned the effectiveness of orally-administered phenylephrine as a nasal decongestant. At least one meta-analysis has concluded that it is more effective than placebos, while other research has not found sufficient evidence to support this claim.
Regulation on sale 
In the United Kingdom, "Sudafed Decongestant" containing 60 mg of pseudoephedrine hydrochloride per tablet is available in packs of 12 tablets from pharmacies and is classified as a Pharmacy Only Medication ("[P]"), so any sale follows a series of questions from the pharmacist to determine if it is safe. Historically, packs of 24 tablets were also available, but the maximum pack size for OTC sales was reduced to 12 tablets as a measure to counteract misuse. The version that contains phenylephrine is not restricted and may be purchased off the shelf from supermarkets and other stores.
In Australia, Sudafed with up to 60 mg of pseudoephedrine is available subject to a pharmacist matching the purchaser's identity to the Project STOP database to determine if the purchase history is consistent with personal use. Under Project STOP, a maximum of one pseudoephedrine containing drugs can be sold over the counter per day. However, doctors still retain the ability to prescribe the drugs. In Queensland, all pharmacists dispensing pseudoephedrine based substances must use the Project STOP database. If identification is not provided, the pharmacist may, at his or her discretion, still provide the medication.
In Canada, Sudafed contains phenylephrine hydrochloride, pseudoephedrine hydrochloride in a 120mg "12 hour time release" capsule, or pseudoephedrine hydrochloride combined with other ingredients (e.g. Ibuprofen).
In the United States, section 711 of the Combat Methamphetamine Epidemic Act of 2005 reclassifies phenylpropanolamine, pseudoephedrine and ephedrine as Schedule Listed Chemicals (SLC). SLCs were reduced by the Federal per-transaction sales limit from 9 grams to 3.6 grams. The amount recently proposed by the Administration requires behind-the-counter storage or locked cabinet storage.
- Suo, Steve (2004). "Shelved solutions". The Oregonian
- Heldeles, L. and Hatton, R. (2006). "Oral phenylephrine: An ineffective replacement for pseudoephedrine?". Journal of Allergy and Clinical Immunology 118 (1): 279–280. doi:10.1016/j.jaci.2006.03.002. PMID 16815167.
- University of Florida (press release) (2006-07-19). "UF researchers question effectiveness of decongestant". Retrieved 2008-03-15.
- Kollar C, Schneider H, Waksman J, Krusinska E. (2007). "Meta-analysis of the efficacy of a single dose of phenylephrine 10 mg compared with placebo in adults with acute nasal congestion due to the common cold". Clinical Therapeutics 29 (6): 1057–1070. doi:10.1016/j.clinthera.2007.05.021. PMID 17692721.
- Hatton, R.C. et al. (2007). "Efficacy and Safety of Oral Phenylephrine: A Systematic Review and Meta-Analysis" (abstract). Annals of Pharmacotherapy 41 (3): 381–390. doi:10.1345/aph.1H679. PMID 17264159.(published online Jan 2007)
- Horak, F.; Zieglmayer, P.; Zieglmayer, R. �; Lemell, P.; Yao, R.; Staudinger, H.; Danzig, M. (2009). "A placebo-controlled study of the nasal decongestant effect of phenylephrine and pseudoephedrine in the Vienna Challenge Chamber". Annals of Allergy, Asthma & Immunology 102 (2): 116. doi:10.1016/S1081-1206(10)60240-2.
- Day, J. H.; Briscoe, M. P.; Ratz, J. D.; Danzig, M.; Yao, R. (2009). "Efficacy of loratadine-montelukast on nasal congestion in patients with seasonal allergic rhinitis in an environmental exposure unit". Annals of Allergy, Asthma & Immunology 102 (4): 328. doi:10.1016/S1081-1206(10)60339-0.
- [dead link]
- sudafed.ca, Johnson & Johnson, Retrieved 23 April 2010
- Human Drug Information. "Legal Requirements for the Sale and Purchase of Drug Products Containing Pseudoephedrine, Ephedrine, and Phenylpropanolamine". Fda.gov. Retrieved 2012-02-13.
- Was the West's methamphetamine epidemic allowed to happen?, a five-part series published in The Oregonian in October 2004
- Official Canadian Website
- Official UK Website